https://orcid.org/0000-0003-0492-6698
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tirath Patel, Fnu Nageeta, Rohab Sohail, Tooba Shaukat Butt, Shyamala Ganesan, Fnu Madhurita, Muhammad Ahmed, Mahrukh Zafar, Wirda Zafar, Mohammad Uzair Zaman, Giustino Varrassi, Mahima Khatri & Satesh Kumar. (2023) Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Annals of Medicine 55:2.
Read now
Read now
Stephen A. Brunton, Ofri Mosenzon & Eugene E. Wright Jr. (2020) Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?. Postgraduate Medicine 132:sup2, pages 48-60.
Read now
Read now
Eugene E. Wright Jr & Vanita R. Aroda. (2020) Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine 132:sup2, pages 26-36.
Read now
Read now
Articles from other publishers (5)
Ahmed Hussein Al-Samiry, Samer Imad Mohammed & Noor Mubder Khalaf. (2024) Proficiency and Knowledge of Community Pharmacists in the Use of Liraglutide and Semaglutide as Weight Reduction Agents. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) 6:1, pages 20-24.
Crossref
Crossref
Aditi R. Saxena, Juan P. Frias, Lisa S. Brown, Donal N. Gorman, Szilard Vasas, Nikolaos Tsamandouras & Morris J. Birnbaum. (2023) Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes. JAMA Network Open 6:5, pages e2314493.
Crossref
Crossref
Mohammed Altigani Abdalla, Ireneous Soyiri, Stephen Atkin & Thozhukat Sathyapalan. (2023) Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials. Journal of Diabetology 14:2, pages 65-73.
Crossref
Crossref
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba & W. David Strain. (2022) Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy 13:2, pages 225-240.
Crossref
Crossref
Serge Halimi. (2021) Les sulfamides hypoglycémiants gardent toujours une place dans le traitement du diabète de type 2 en 2021. Les points forts du dossier des sulfamides hypoglycémiants. Médecine des Maladies Métaboliques 15:1, pages 53-61.
Crossref
Crossref